MLTX — MoonLake Immunotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $2.53bn
- $2.09bn
- 35
- 22
- 28
- 18
Annual cashflow statement for MoonLake Immunotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -53.6 | -64.5 | -44.1 | -121 |
| Depreciation | ||||
| Non-Cash Items | 14 | 10 | 7.51 | 7.06 |
| Other Non-Cash Items | ||||
| Changes in Working Capital | 4.48 | -1.43 | -6.22 | -3.78 |
| Change in Accounts Receivable | ||||
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Cash from Operating Activities | -35.2 | -55.9 | -42.8 | -117 |
| Capital Expenditures | -0.051 | -0.016 | -0.285 | -0.52 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | — | -32.3 | -24.9 | -205 |
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Cash from Investing Activities | -0.051 | -32.3 | -25.2 | -206 |
| Financing Cash Flow Items | — | 135 | -2.75 | -1.47 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 43.3 | 120 | 480 | 51.3 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 8.04 | 31.5 | 412 | -271 |